This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Foundation grant will help NYC-based nonprofit expand reach of its innovative curriculum to 50 schools in Baltimore and Houston Funding will also support film screening tour of award-winning...
Fourth quarter revenues of $2.29 billion, down 1.9% from 2022 Fourth quarter reported diluted earnings per share ("EPS") of $1.70, up 95.4% from 2022; and adjusted diluted EPS of $2.15, up 8.6%...
Xylazine found in 1 in 12 specimens tested, finds new 'Drug Misuse in America' Health Trends® report on the rising polysubstance crisis SECAUCUS, N.J., Dec. 19, 2023 /PRNewswire/ -- Quest...
Quest will provide research consulting, laboratory testing and data analytics services to generate diagnostics insights supporting population health strategy for hepatitis C SECAUCUS, N.J., Dec....
Third quarter revenues of $2.30 billion, down 7.7% from 2022 Third quarter reported diluted earnings per share ("EPS") of $1.96, down 9.7% from 2022; and adjusted diluted EPS of $2.22, down 5.9%...
Second quarter revenues of $2.34 billion, down 4.7% from 2022 Second quarter reported diluted earnings per share ("EPS") of $2.05, up 4.6% from 2022; and adjusted diluted EPS of $2.30, down 2.5%...
Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer SECAUCUS, N.J. and MELBOURNE, Australia, July 13, 2023 /
June 2023 For more information or to schedule an interview with one of our medical experts, please email mediacontact@questdiagnostics.com. Breaking Science News: Only one in three adults (34%)...
Beginning February 2023, Quest Diagnostics plans to discontinue providing a monthly COVID-19 media statement, including monthly COVID-19 volume and turnaround time figures. Instead, this media...
First quarter revenues of $2.33 billion, down 10.7% from 2022 First quarter reported diluted earnings per share ("EPS") of $1.78, down 39.0% from 2022; and adjusted diluted EPS of $2.04, down...